Hammerhead Ribozymes Targeted to the FBN1 mRNA Can Discriminate a Single Base Mismatch between Ribozyme and Target
- 28 August 1998
- journal article
- Published by Elsevier BV in Biochemical and Biophysical Research Communications
- Vol. 249 (3), 804-810
- https://doi.org/10.1006/bbrc.1998.9241
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Delivery of a hammerhead ribozyme specifically down-regulates the production of fibrillin-1 by cultured dermal fibroblastsHuman Molecular Genetics, 1996
- Suppression of the Malignant Phenotype of Melanoma Cells by Anti-Oncogene RibozymesJournal of Investigative Dermatology, 1996
- RNA enzymes as tools for gene ablationCurrent Opinion in Biotechnology, 1995
- Controlled, targeted, intracellular expression of ribozymes: Progress and problemsTrends in Biotechnology, 1995
- A mutation in FBN1 disrupts profibrillin processing and results in isolated skeletal features of the Marfan syndrome.JCI Insight, 1995
- Quantitative differences in biosynthesis and extracellular deposition of fibrillin in cultured fibroblasts distinguish five groups of Marfan syndrome patients and suggest distinct pathogenetic mechanisms.JCI Insight, 1994
- Four Novel FBN1 Mutations: Significance for Mutant Transcript Level and EGF-like Domain Calcium Binding in the Pathogenesis of Marfan SyndromeGenomics, 1993
- A novel fibrillin mutation in the Marfan syndrome which could disrupt calcium binding of the epidermal growth factor-like moduleHuman Molecular Genetics, 1993
- Linkage of Marfan syndrome and a phenotypically related disorder to two different fibrillin genesNature, 1991
- The Marfan Syndrome: Diagnosis and ManagementNew England Journal of Medicine, 1979